Mir-134: A Human Cancer Suppressor?

Jingyu Pan,Feng Zhang,Chengcao Sun,Shujun Li,Guang Li,Fengyun Gong,Bo Tao,Jing He,Rui‐Xi Hua,Weidong Hu,Yuan Zhu,Xin Wang,Qi‐qiang He,Dejia Li

DOI: https://doi.org/10.1016/j.omtn.2016.11.003

2017-01-01

Abstract:MicroRNAs (miRNAs) are small noncoding RNAs approximately 20–25 nt in length, which play crucial roles through directly binding to corresponding 3′ UTR of targeted mRNAs. It has been reported that miRNAs are involved in numerous of diseases, including cancers. Recently, miR-134 has been identified to dysregulate in handles of human cancers, such as lung cancer, glioma, breast cancer, colorectal cancer, and so on. Increasing evidence indicates that miR-134 is essential for human carcinoma and participates in tumor cell proliferation, apoptosis, invasion and metastasis, drug resistance, as well as cancer diagnosis, treatment, and prognosis. Nevertheless, its roles in human cancer are still ambiguous, and its mechanisms are sophisticated as well, referring to a variety of targets and signal pathways, such as STAT5B, KRAS, MAPK/ERK signal pathway, Notch pathway, etc. Herein, we review the crucial roles of miR-134 in scores of human cancers via analyzing latest investigations, which might provide evidence for cancer diagnose, treatment, prognosis, or further investigations. MicroRNAs (miRNAs) are small noncoding RNAs approximately 20–25 nt in length, which play crucial roles through directly binding to corresponding 3′ UTR of targeted mRNAs. It has been reported that miRNAs are involved in numerous of diseases, including cancers. Recently, miR-134 has been identified to dysregulate in handles of human cancers, such as lung cancer, glioma, breast cancer, colorectal cancer, and so on. Increasing evidence indicates that miR-134 is essential for human carcinoma and participates in tumor cell proliferation, apoptosis, invasion and metastasis, drug resistance, as well as cancer diagnosis, treatment, and prognosis. Nevertheless, its roles in human cancer are still ambiguous, and its mechanisms are sophisticated as well, referring to a variety of targets and signal pathways, such as STAT5B, KRAS, MAPK/ERK signal pathway, Notch pathway, etc. Herein, we review the crucial roles of miR-134 in scores of human cancers via analyzing latest investigations, which might provide evidence for cancer diagnose, treatment, prognosis, or further investigations. Cancers, the leading cause of death-related diseases in humans, have long been severe threats to human health. Multitudes of people are diagnosed with or dead from cancers every year. In America, cancers have been the second major cause of death, which is barely inferior to heart diseases. Siegel et al.1Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2015.CA Cancer J. Clin. 2015; 65: 5-29Crossref PubMed Scopus (9693) Google Scholar reported that there might be 1,658,370 newly diagnosed cancer patients and 589,430 cancer deaths in 2015. In China, Chen et al.2Chen W. Zheng R. Baade P.D. Zhang S. Zeng H. Bray F. Jemal A. Yu X.Q. He J. Cancer statistics in China, 2015.CA Cancer J. Clin. 2016; 66: 115-132Crossref PubMed Scopus (7641) Google Scholar collected information of 72 cancer registries, which indicated about 12,000 new cancer cases occur every day, and it would be increased to approximately 4,292,000 new cases in 2016. Moreover, cancers lead to increases in severe disease burden and hamper economic development.3Brown T. Young C. Rushton L. British Occupational Cancer Burden Study GroupOccupational cancer in Britain. Remaining cancer sites: Brain, bone, soft tissue sarcoma and thyroid.Br. J. Cancer. 2012; 107: S85-S91Crossref PubMed Scopus (0) Google Scholar Therefore, it is imperative to investigate the correlation between cancers and their risk factors, especially the molecular mechanisms of cancers, which might contribute to develop novel and effective pharmaceutics or treatments. MicroRNAs (miRNAs) are characterized as a group of small noncoding RNAs approximately 20–25 nt in length, which play key roles by binding to corresponding 3′ UTR of targeted mRNAs.4Fabian M.R. Sonenberg N. Filipowicz W. Regulation of mRNA translation and stability by microRNAs.Annu. Rev. Biochem. 2010; 79: 351-379Crossref PubMed Scopus (1624) Google Scholar, 5Grosswendt S. Filipchyk A. Manzano M. Klironomos F. Schilling M. Herzog M. Gottwein E. Rajewsky N. Unambiguous identification of miRNA:target site interactions by different types of ligation reactions.Mol. Cell. 2014; 54: 1042-1054Abstract Full Text Full Text PDF PubMed Scopus (134) Google Scholar, 6Liu X. Zheng Q. Vrettos N. Maragkakis M. Alexiou P. Gregory B.D. Mourelatos Z. A MicroRNA precursor surveillance system in quality control of MicroRNA synthesis.Mol. Cell. 2014; 55: 868-879Abstract Full Text Full Text PDF PubMed Scopus (38) Google Scholar miRNAs regulate approximately 30%–50% of human gene expression.7Bartel D.P. MicroRNAs: Target recognition and regulatory functions.Cell. 2009; 136: 215-233Abstract Full Text Full Text PDF PubMed Scopus (12166) Google Scholar, 8Rajewsky N. microRNA target predictions in animals.Nat. Genet. 2006; 38: S8-S13Crossref PubMed Scopus (829) Google Scholar Recently, numerous researches have reported the roles of miRNAs in several human diseases, especially in cancers. Massive evidence indicates miRNAs could function as modulators in multiple pathological and biological progressions, such as cancer cell differentiation, proliferation, apoptosis, etc. Additionally, miRNAs are described as a kind of emerging clinical, diagnostic, and prognostic biomarker, as well as treatment approach.9Calin G.A. Croce C.M. MicroRNA signatures in human cancers.Nat. Rev. Cancer. 2006; 6: 857-866Crossref PubMed Scopus (5605) Google Scholar, 10Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function.Cell. 2004; 116: 281-297Abstract Full Text Full Text PDF PubMed Scopus (23590) Google Scholar Sun et al.11Sun C. Li S. Yang C. Xi Y. Wang L. Zhang F. Li D. MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6.Biochem. Biophys. Res. Commun. 2016; 471: 82-88Crossref PubMed Scopus (85) Google Scholar, 12Sun C. Sang M. Li S. Sun X. Yang C. Xi Y. Wang L. Zhang F. Bi Y. Fu Y. Li D. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met.Oncotarget. 2015; 6: 39756-39792Crossref PubMed Scopus (84) Google Scholar, 13Sun C.C. Li S.J. Zhang F. Pan J.Y. Wang L. Yang C.L. Xi Y.Y. Li J. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer.Oncotarget. 2016; 7: 21510-21526Crossref PubMed Scopus (60) Google Scholar, 14Sun C. Liu Z. Li S. Yang C. Xue R. Xi Y. Wang L. Wang S. He Q. Huang J. et al.Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation.Oncotarget. 2015; 6: 25533-25574Crossref PubMed Scopus (89) Google Scholar, 15Sun C. Huang C. Li S. Yang C. Xi Y. Wang L. Zhang F. Fu Y. Li D. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development.Oncotarget. 2016; 7: 8341-8359Crossref PubMed Scopus (80) Google Scholar have explored the association between miRNAs and non-small cell lung cancer (NSCLC), revealing miR-139-5p, miR-187, miR-206, miR-326, and miR-329 were downregulated in lung cancer cell lines and tissues and played tumor-suppressive roles by targeting specific 3′ UTR of mRNAs for several oncogenes. However, there are also scores of miRNAs overexpressed in various cancers, including gastric cancer, bladder carcinoma, NSCLC, breast cancer, and so on, which might promote cancer development and malignancy.16Liu Z. Zhu J. Cao H. Ren H. Fang X. miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer.Int. J. Oncol. 2012; 40: 1553-1560PubMed Google Scholar, 17Zhao G. Zhou X. Fang T. Hou Y. Hu Y. Hyaluronic acid promotes the expression of progesterone receptor membrane component 1 via epigenetic silencing of miR-139-5p in human and rat granulosa cells.Biol. Reprod. 2014; 91: 116Crossref PubMed Scopus (12) Google Scholar, 18Ma L. Teruya-Feldstein J. Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature. 2007; 449: 682-688Crossref PubMed Scopus (1968) Google Scholar, 19Ibrahim S.A. Yip G.W. Stock C. Pan J.W. Neubauer C. Poeter M. Pupjalis D. Koo C.Y. Kelsch R. Schüle R. et al.Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.Int. J. Cancer. 2012; 131: E884-E896Crossref PubMed Scopus (84) Google Scholar, 20Yu T. Liu L. Li J. Yan M. Lin H. Liu Y. Chu D. Tu H. Gu A. Yao M. MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN.Oncotarget. 2015; 6: 30239-30250Crossref PubMed Scopus (77) Google Scholar Moreover, investigations suggested that miRNAs functioned as vital modulators in DNA damage with ionizing irradiation engendered, and, what's more, a subset of miRNA's signature has been verified that could respond to radiotherapy in head and neck squamous cell carcinoma (HNSCC).21Liu N. Boohaker R.J. Jiang C. Boohaker J.R. Xu B. A radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas.Oncotarget. 2015; 6: 34649-34657Crossref PubMed Scopus (0) Google Scholar Chen and colleagues22Chen L. Kang C. miRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarks.Oncotarget. 2015; 6: 38628-38642PubMed Google Scholar found few miRNA-based treatments were applied for clinical trials, but they were not appropriate to glioblastoma. However, we suppose that miRNA-based medicine might be a novel and promising method against various tumors in the future, when the roles and mechanisms of miRNAs in cancer are clearly discovered. miR-134 belongs to chromosome 14q32 miRNAs clusters, and it has been reported that DLK1-DIO3 that appears in a differentially methylated region leads to abnormal expression of 14q32 gene clusters.23Seitz H. Royo H. Bortolin M.L. Lin S.P. Ferguson-Smith A.C. Cavaillé J. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain.Genome Res. 2004; 14: 1741-1748Crossref PubMed Scopus (379) Google Scholar, 24Luk J.M. Burchard J. Zhang C. Liu A.M. Wong K.F. Shek F.H. Lee N.P. Fan S.T. Poon R.T. Ivanovska I. et al.DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival.J. Biol. Chem. 2011; 286: 30706-30713Crossref PubMed Scopus (102) Google Scholar miR-134 was found to regulate dendritic spine development through targeting Limk1 mRNA in rat hippocampal neurons.25Schratt G.M. Tuebing F. Nigh E.A. Kane C.G. Sabatini M.E. Kiebler M. Greenberg M.E. A brain-specific microRNA regulates dendritic spine development.Nature. 2006; 439: 283-289Crossref PubMed Scopus (1264) Google Scholar Recently, it has been reported that miR-134 also plays a crucial role in enhancing hippocampal memory and synaptic plasticity through 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside treatment in normal mice.26Chen T. Yang Y.J. Li Y.K. Liu J. Wu P.F. Wang F. Chen J.G. Long L.H. Chronic administration tetrahydroxystilbene glucoside promotes hippocampal memory and synaptic plasticity and activates ERKs, CaMKII and SIRT1/miR-134 in vivo.J. Ethnopharmacol. 2016; 190: 74-82Crossref PubMed Google Scholar Fiore et al.27Fiore R. Rajman M. Schwale C. Bicker S. Antoniou A. Bruehl C. Draguhn A. Schratt G. MiR-134-dependent regulation of Pumilio-2 is necessary for homeostatic synaptic depression.EMBO J. 2014; 33: 2231-2246Crossref PubMed Scopus (41) Google Scholar discovered miR-134 acted as a vital regulator in homeostatic synaptic repression by targeting Pumilio-2. Furthermore, miR-134 was monitored for involvement in epilepticus, as evidenced by the fact that miR-134 protected neurons and decreased epilepticus seizure.28Henshall D.C. MicroRNAs in the pathophysiology and treatment of status epilepticus.Front. Mol. Neurosci. 2013; 6: 37Crossref PubMed Scopus (46) Google Scholar Recently, miR-134 has been reported to participate in a majority of carcinomas and tumors. Upregulation of miR-134 was observed in lung tumor, pancreatic cancer, colon cancer, and prostate cancer, whereas downregulation of miR-134 was also found in a variety of cancers, including NSCLC, glioblastomas, breast cancer, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, osteosarcoma, etc. (Table 1). These findings suggested miR-134 might present some characters in tumor progression. Consistently, it has been reported that miR-134 played a critical role in cancer cell proliferation, apoptosis, invasion and metastasis, drug resistance, as well as cancer diagnosis, treatment, and prognosis. For instance, Liu et al.29Liu Y. Zhang M. Qian J. Bao M. Meng X. Zhang S. Zhang L. Zhao R. Li S. Cao Q. et al.miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.DNA Cell Biol. 2015; 34: 429-436Crossref PubMed Scopus (42) Google Scholar found miR-134 markedly decreased in renal cell carcinoma cells and tissues, and restoration of its expression was able to refrain cell proliferation by silencing G0/G1 phase. Overexpressed miR-134 could also refrain cell metastasis in endometrial tumor.30Gao Y. Liu T. Huang Y. MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins.FEBS Lett. 2015; 589: 207-214Crossref PubMed Google Scholar Furthermore, miR-134 could also regulate drug resistance through targeting ABCC1 in breast cancer cells; meanwhile, it also participated in drug resistance in ovarian carcinoma and SCLC cells, suggesting the mechanisms of miR-134 in different carcinomas might be diverse. In addition, miR-134 targeted multiple genes in tumors, such as KRAS, STAT5B, Nanog, FOXM1, EGFR, etc. (Table 1). Despite functioning as a modulator in cancers, miR-134 affected abundant and complicated signal pathways, including MAPK/ERK signal pathway, EGFR pathway, Notch pathway, etc.Table 1miR-134 Deregulates in Various Cancers and Their Target GenesCancer TypeTarget GeneReferencemiR-134 Downlung cancerDPD gene90Hirota T. Date Y. Nishibatake Y. Takane H. Fukuoka Y. Taniguchi Y. Burioka N. Shimizu E. Nakamura H. Otsubo K. Ieiri I. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues.Lung Cancer. 2012; 77: 16-23Abstract Full Text Full Text PDF PubMed Scopus (41) Google ScholarNSCLConcogenic CCND134Sun C.C. Li S.J. Li D.J. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1.Oncotarget. 2016; 7: 35960-35978Crossref PubMed Scopus (69) Google ScholarNSCLCFOXM169Li J. Wang Y. Luo J. Fu Z. Ying J. Yu Y. Yu W. miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells.FEBS Lett. 2012; 586: 3761-3765Crossref PubMed Scopus (106) Google ScholarNSCLCEGFR35Qin Q. Wei F. Zhang J. Wang X. Li B. miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor.J. Cell. Mol. Med. 2016; 20: 1974-1983Crossref PubMed Google ScholargliomasKRAS39Zhao Y. Pang D. Wang C. Zhong S. Wang S. MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway.Tumour Biol. 2016; 37: 11485-11493Crossref PubMed Google Scholargliomas—79Lages E. Guttin A. El Atifi M. Ramus C. Ipas H. Dupré I. Rolland D. Salon C. Godfraind C. deFraipont F. et al.MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes.PLoS ONE. 2011; 6: e20600Crossref PubMed Scopus (90) Google Scholar, 91Zhong J. Li B. Reduced expression of microRNA-134 correlates with malignancy and poor prognosis in human glioma.J. Clin. Neurosci. 2015; 22: 583-587Abstract Full Text Full Text PDF PubMed Google ScholarglioblastomasKRAS, STAT5B40Zhang Y. Kim J. Mueller A.C. Dey B. Yang Y. Lee D.H. Hachmann J. Finderle S. Park D.M. Christensen J. et al.Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.Cell Death Differ. 2014; 21: 720-734Crossref PubMed Scopus (49) Google ScholarglioblastomasNanog41Niu C.S. Yang Y. Cheng C.D. MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression.Int. J. Oncol. 2013; 42: 1533-1540Crossref PubMed Scopus (51) Google Scholarbreast cancerC/EBPα46Zhang J. Ma Y. Wang S. Chen F. Gu Y. C/EBPα inhibits proliferation of breast cancer cells via a novel pathway of miR-134/CREB.Int. J. Clin. Exp. Pathol. 2015; 8: 14472-14478PubMed Google Scholarbreast cancerHER247Leivonen S.K. Sahlberg K.K. Mäkelä R. Due E.U. Kallioniemi O. Børresen-Dale A.L. Perälä M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.Mol. Oncol. 2014; 8: 93-104Crossref PubMed Scopus (102) Google Scholarbreast cancer—111Tahiri A. Leivonen S.K. Lüders T. Steinfeld I. Ragle Aure M. Geisler J. Mäkelä R. Nord S. Riis M.L. Yakhini Z. et al.Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.Carcinogenesis. 2014; 35: 76-85Crossref PubMed Scopus (77) Google Scholarrenal cell carcinomaKRAS29Liu Y. Zhang M. Qian J. Bao M. Meng X. Zhang S. Zhang L. Zhao R. Li S. Cao Q. et al.miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.DNA Cell Biol. 2015; 34: 429-436Crossref PubMed Scopus (42) Google Scholarrenal cell carcinoma—112Ge Y.Z. Xu L.W. Xu Z. Wu R. Xin H. Zhu M. Lu T.Z. Geng L.G. Liu H. Zhou C.C. et al.Expression Profiles and Clinical Significance of MicroRNAs in Papillary Renal Cell Carcinoma: A STROBE-Compliant Observational Study.Medicine (Baltimore). 2015; 94: e767Crossref PubMed Scopus (21) Google Scholarcolorectal cancerEGFR, PIK3CA43El-Daly S.M. Abba M.L. Patil N. Allgayer H. miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.Sci. Rep. 2016; 6: 24720Crossref PubMed Google Scholarcolorectal cancer—44Xie Y. Song J. Zong Q. Wang A. Yang Y. Liu F. Meng X. Decreased Expression of MIR-134 and its Clinical Significance in Human Colorectal Cancer.Hepatogastroenterology. 2015; 62: 615-619PubMed Google Scholargastric cancer—94Haller F. von Heydebreck A. Zhang J.D. Gunawan B. Langer C. Ramadori G. Wiemann S. Sahin O. Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31.J. Pathol. 2010; 220: 71-86Crossref PubMed Scopus (95) Google Scholar, 95Wang Z. Wang J. Yang Y. Hao B. Wang R. Li Y. Wu Q. Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer.J. Exp. Clin. Cancer Res. 2013; 32: 76Crossref PubMed Scopus (41) Google Scholarhepatocellular carcinomaKRAS72Yin C. Wang P.Q. Xu W.P. Yang Y. Zhang Q. Ning B.F. Zhang P.P. Zhou W.P. Xie W.F. Chen W.S. Zhang X. Hepatocyte nuclear factor-4α reverses malignancy of hepatocellular carcinoma through regulating miR-134 in the DLK1-DIO3 region.Hepatology. 2013; 58: 1964-1976Crossref PubMed Scopus (57) Google Scholarhepatocellular carcinomaITGB170Zha R. Guo W. Zhang Z. Qiu Z. Wang Q. Ding J. Huang S. Chen T. Gu J. Yao M. He X. Genome-wide screening identified that miR-134 acts as a metastasis suppressor by targeting integrin β1 in hepatocellular carcinoma.PLoS ONE. 2014; 9: e87665Crossref PubMed Scopus (56) Google ScholarHNSCC—83Salazar C. Nagadia R. Pandit P. Cooper-White J. Banerjee N. Dimitrova N. Coman W.B. Punyadeera C. A novel saliva-based microRNA biomarker panel to detect head and neck cancers.Cell Oncol. (Dordr.). 2014; 37: 331-338Crossref PubMed Scopus (62) Google Scholarendometrial cancerPOGLUT130Gao Y. Liu T. Huang Y. MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins.FEBS Lett. 2015; 589: 207-214Crossref PubMed Google Scholarosteosarcoma92Bao Y. Peng L. Ma J. Liu K. Li W. Decreased miR-134 expression and its tumor-suppressive function in human osteosarcoma.Genet. Mol. Res. 2015; 14: 16771-16781Crossref PubMed Google ScholarmiR-134 Uplung tumors—110Mirzadeh Azad F. Naeli P. Malakootian M. Baradaran A. Tavallaei M. Ghanei M. Mowla S.J. Two lung development-related microRNAs, miR-134 and miR-187, are differentially expressed in lung tumors.Gene. 2016; 577: 221-226Crossref PubMed Scopus (18) Google ScholarNSCLCYKT688Ruiz-Martinez M. Navarro A. Marrades R.M. Viñolas N. Santasusagna S. Muñoz C. Ramírez J. Molins L. Monzo M. YKT6 expression, exosome release, and survival in non-small cell lung cancer.Oncotarget. 2016; Crossref PubMed Scopus (35) Google ScholarHNSCCWWOX gene64Liu C.J. Shen W.G. Peng S.Y. Cheng H.W. Kao S.Y. Lin S.C. Chang K.W. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene.Int. J. Cancer. 2014; 134: 811-821Crossref PubMed Scopus (75) Google Scholarpancreatic cancer—62Li A. Yu J. Kim H. Wolfgang C.L. Canto M.I. Hruban R.H. Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls.Clin. Cancer Res. 2013; 19: 3600-3610Crossref PubMed Scopus (174) Google Scholarcolon cancer—42Ahmed F.E. Ahmed N.C. Vos P.W. Bonnerup C. Atkins J.N. Casey M. Nuovo G.J. Naziri W. Wiley J.E. Mota H. Allison R.R. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.Cancer Genomics Proteomics. 2013; 10: 93-113PubMed Google Scholarprostate cancer—45Wang W.L. Chatterjee N. Chittur S.V. Welsh J. Tenniswood M.P. Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells.Mol. Cancer. 2011; 10: 58Crossref PubMed Scopus (98) Google Scholaruveal melanoma—78Venkatesan N. Kanwar J. Deepa P.R. Khetan V. Crowley T.M. Raguraman R. Sugneswari G. Rishi P. Natarajan V. Biswas J. Krishnakumar S. Clinico-pathological association of delineated miRNAs in uveal melanoma with monosomy 3/Disomy 3 chromosomal aberrations.PLoS ONE. 2016; 11: e0146128Crossref PubMed Google ScholarSCC of tongue—80Wong T.S. Liu X.B. Wong B.Y. Ng R.W. Yuen A.P. Wei W.I. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue.Clin. Cancer Res. 2008; 14: 2588-2592Crossref PubMed Scopus (572) Google ScholarNSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; SCC of tongue, squamous cell carcinoma of tongue. Open table in a new tab NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; SCC of tongue, squamous cell carcinoma of tongue. In this review, we synthesize the roles and mechanisms of miR-134 in cancer cell proliferation, apoptosis, invasion and metastasis, drug resistance, cancer diagnosis as well as patients' survival and prognosis, to provide intuitionistic evidence for clinical applications and further investigations in the future. Increasing evidence indicates miR-134 associates with various genes mediating cancer cell proliferation. Cyclin D and CDK4 have been discovered to be upregulated in a variety of human cancer cells.31Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment.J. Clin. Oncol. 2006; 24: 1770-1783Crossref PubMed Scopus (725) Google Scholar P21 gene, a cell growth regulator, is found to involve in cancerous cell-cycle arrest at G1 phase.32Harper J.W. Adami G.R. Wei N. Keyomarsi K. Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.Cell. 1993; 75: 805-816Abstract Full Text PDF PubMed Scopus (4945) Google Scholar, 33Harper J.W. Elledge S.J. Keyomarsi K. Dynlacht B. Tsai L.H. Zhang P. Dobrowolski S. Bai C. Connell-Crowley L. Swindell E. et al.Inhibition of cyclin-dependent kinases by p21.Mol. Biol. Cell. 1995; 6: 387-400Crossref PubMed Google Scholar Sun et al.34Sun C.C. Li S.J. Li D.J. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1.Oncotarget. 2016; 7: 35960-35978Crossref PubMed Scopus (69) Google Scholar disclosed that miR-134 increased p21 expression and suppressed cyclin D1, cyclin D2, and CDK4 proteins expression in SPC-A1 and A549 cells, which indicated miR-134 could repress NSCLC cell proliferation. In another study, increasing miR-134 expression suppressed lung cancer cell proliferation by downregulating EGFR.35Qin Q. Wei F. Zhang J. Wang X. Li B. miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor.J. Cell. Mol. Med. 2016; 20: 1974-1983Crossref PubMed Google Scholar It has been reported that EGFR possessed effect of resistance to cancer procession and development.36Kari C. Chan T.O. Rocha de Quadros M. Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage.Cancer Res. 2003; 63: 1-5PubMed Google Scholar MiR-134 was also found to associate with cancer treatment as well as trigger numerous pathways, such as the MAPK pathway and PI3K-AKT-mTOR pathway.37Yu H.A. Riely G.J. Lovly C.M. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Clin. Cancer Res. 2014; 20: 5898-5907Crossref PubMed Scopus (59) Google Scholar Qin et al. found EGFR was an appropriate target of miR-134 in NSCLC cells, and upregulation of miR-134 inhibited the EGFR-correlated signal pathway. After transfection with miR-134 mimics, the protein level of p-Akt was downregulated in H1299, H520, as well as A549 cell lines; pERK1/2 yield was reduced in A549, H520, and H1975 cell lines; p-STAT3 expression was decreased in H1299 and H520 cells. These data suggested miR-134 repressed NSCLC cell proliferation via targeting EGFR and activating corresponding pathways.35Qin Q. Wei F. Zhang J. Wang X. Li B. miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor.J. Cell. Mol. Med. 2016; 20: 1974-1983Crossref PubMed Google Scholar Consistently, that evidence uncovered that mutant KRAS played a critical modulator in the EGFR signaling cascade through repressing miR-4689 to modulate both PI3K/AKT and RAS/MAPK pathways in colorectal cancer.38Hiraki M. Nishimura J. Takahashi H. Wu X. Takahashi Y. Miyo M. Nishida N. Uemura M. Hata T. Takemasa I. et al.Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer.Mol. Ther. Nucleic Acids. 2015; 4: e231Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar In addition, miR-134 was also demonstrated to downregulate in glioma tumor and overexpressed miR-134 inhibited glioma cell growth through targeting KRAS and activating the ERK pathway.39Zhao Y. Pang D. Wang C. Zhong S. Wang S. MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway.Tumour Biol. 2016; 37: 11485-11493Crossref PubMed Google Scholar Overexpression of miR-134 significantly repressed cell proliferation and xenograft development in another investigation of glioblastoma tumor.40Zhang Y. Kim J. Mueller A.C. Dey B. Yang Y. Lee D.H. Hachmann J. Finderle S. Park D.M. Christensen J. et al.Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.Cell Death Differ. 2014; 21: 720-734Crossref PubMed Scopus (49) Google Scholar Zhang et al.40Zhang Y. Kim J. Mueller A.C. Dey B. Yang Y. Lee D.H. Hachmann J. Finderle S. Park D.M. Christensen J. et al.Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.Cell Death Differ. 2014; 21: 720-734Crossref PubMed Scopus (49) Google Scholar confirmed that miR-134 expression was remarkably decreased in glioblastoma and had an opposite correlation with MET, and other proteins, including RTKs EGFR and PDGFR. Additionally, miR-134 also functioned as a tumor suppressor via downregulating KRAS and STAT5B expression.40Zhang Y. Kim J. Mueller A.C. Dey B. Yang Y. Lee D.H. Hachmann J. Finderle S. Park D.M. Christensen J. et al.Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.Cell Death Differ. 2014; 21: 720-734Crossref PubMed Scopus (49) Google Scholar It was also verified in another study about glioblastoma that miR-134 suppressed tumor progression and proliferation in vivo and in vitro.41Niu C.S. Yang Y. Cheng C.D. MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression.Int. J. Oncol. 2013; 42: 1533-1540Crossref PubMed Scopus (51) Google Scholar Liu et al.29Liu Y. Zhang M. Qian J. Bao M. Meng X. Zhang S. Zhang L. Zhao R. Li S. Cao Q. et al.miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.DNA Cell Biol. 2015; 34: 429-436Crossref PubMed Scopus (42) Google Scholar found miR-134 expression markedly decreased in renal cell carcinoma cells and tissues compared with that of normal cells and tissues, and restoration of its expression was able to refrain cell proliferation by silencing G0/G1 phase. In addition, miR-134 expression was discovered to increase in colon cancer patients' stool,42Ahmed F.E. Ahmed N.C. Vos P.W. Bonnerup C. Atkins J.N. Casey M. Nuovo G.J. Naziri W. Wiley J.E. Mota H. Allison R.R. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.Cancer Genomics Proteomics. 2013; 10: 93-113PubMed Google Scholar whereas it was found to have an opposite outcome of expression in colorectal tumor that remarkably decreased in tumor tissues and cell lines. Overexpression of miR-134 resulted in repression of colorectal cancer cell proliferation and growth.43El-Daly S.M. Abba M.L. Patil N.